Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,30,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68718,myelin oligodendrocyte glycoprotein (20 ug) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68722,myelin oligodendrocyte glycoprotein (20 ug) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,8,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68724,myelin oligodendrocyte glycoprotein (20 ug) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,7,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,14,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68726,myelin oligodendrocyte glycoprotein (20 ug) 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,7,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,14.3,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68734,myelin oligodendrocyte glycoprotein (200 ul) 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,8,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,75,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68735,myelin oligodendrocyte glycoprotein (200 ul)